| EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes JJM Van Dongen, L Lhermitte, S Böttcher, J Almeida, ... Leukemia 26 (9), 1908-1975, 2012 | 1033 | 2012 |
| EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols T Kalina, J Flores-Montero, VHJ Van Der Velden, M Martin-Ayuso, ... Leukemia 26 (9), 1986-2010, 2012 | 816 | 2012 |
| New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis … E Pérez-Persona, MB Vidriales, G Mateo, R García-Sanz, MV Mateos, ... Blood, The Journal of the American Society of Hematology 110 (7), 2586-2592, 2007 | 623 | 2007 |
| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 589 | 2010 |
| Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ... Leukemia 31 (10), 2094-2103, 2017 | 586 | 2017 |
| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation B Paiva, MB Vidriales, J Cerveró, G Mateo, JJ Pérez, MA Montalbán, ... Blood, The Journal of the American Society of Hematology 112 (10), 4017-4023, 2008 | 513 | 2008 |
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation … B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ... Blood, The Journal of the American Society of Hematology 119 (3), 687-691, 2012 | 325 | 2012 |
| Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells M Urashima, A Ogata, D Chauhan, M Hatziyanni, MB Vidriales, ... | 304 | 1996 |
| Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials JJ Lahuerta, B Paiva, MB Vidriales, L Cordón, MT Cedena, N Puig, ... Journal of clinical oncology: official journal of the American Society of …, 2017 | 299 | 2017 |
| Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma B Paiva, J Martinez-Lopez, MB Vidriales, MV Mateos, MA Montalban, ... J Clin Oncol 29 (12), 1627-1633, 2011 | 285 | 2011 |
| Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy G Mateo, MA Montalbán, MB Vidriales, JJ Lahuerta, MV Mateos, ... Journal of Clinical Oncology 26 (16), 2737-2744, 2008 | 283 | 2008 |
| Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders B Paiva, J Almeida, M Pérez‐Andrés, G Mateo, A López, A Rasillo, ... Cytometry Part B: Clinical Cytometry 78 (4), 239-252, 2010 | 267 | 2010 |
| Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma J Flores‐Montero, R de Tute, B Paiva, JJ Perez, S Böttcher, H Wind, ... Cytometry Part B: Clinical Cytometry 90 (1), 61-72, 2016 | 247 | 2016 |
| Measurable residual disease by next-generation flow cytometry in multiple myeloma B Paiva, R Martinez-Martinez, R Maldonado, A Sureda, R Garcia-Sanz, ... J. Clin. Oncol., 2020 | 213 | 2020 |
| Immunophenotypic analysis of Waldenstrom's macroglobulinemia JF San Miguel, MB Vidriales, E Ocio, G Mateo, F Sanchez-Guijo, ... Seminars in oncology 30 (2), 187-195, 2003 | 210 | 2003 |
| Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry N Puig, ME Sarasquete, A Balanzategui, J Martinez, B Paiva, H Garcia, ... Leukemia 28 (2), 391-397, 2014 | 205 | 2014 |
| Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value MB Vidriales, JJ Pérez, MC López-Berges, N Gutiérrez, J Ciudad, P Lucio, ... Blood 101 (12), 4695-4700, 2003 | 190 | 2003 |
| The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells L López-Corral, NC Gutiérrez, MB Vidriales, MV Mateos, A Rasillo, ... Clinical cancer research 17 (7), 1692-1700, 2011 | 180 | 2011 |
| Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile B Paiva, T Paino, JM Sayagues, M Garayoa, L San-Segundo, M Martín, ... Blood, The Journal of the American Society of Hematology 122 (22), 3591-3598, 2013 | 171 | 2013 |
| Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry RJP de Magalhães, MB Vidriales, B Paiva, C Fernandez-Gimenez, ... Haematologica 98 (1), 79, 2013 | 163 | 2013 |
